2022 World Conference on Lung Cancer (ePosters)-EP02.01-008. Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas

EP02.01-008. Clinicopathological Features of Rare but Targetable Mutations in Surgically Resected Lung Carcinomas

Pdf Summary

This study investigated the clinicopathological features and disease-free survival (DFS) of surgically resected lung carcinomas with rare but targetable mutations, including KRASG12C, BRAF, ALK fusion, and METex14 skipping alterations. The researchers analyzed data from lung cancer patients who underwent resection between 2015 and 2021 at two academic centers. Patients who received definitive radiotherapy were excluded from the study.<br /><br />The results showed that there were significant differences in age distribution and smoking behavior among the mutation groups, but no significant differences in PD-L1 status. Regarding DFS, no significant differences were found between the mutation groups. However, the KRASG12C group had the lowest median DFS (785 days). Furthermore, within the KRASG12C group, adjuvant therapy was associated with a significantly better DFS compared to no therapy. Median DFS for patients receiving adjuvant therapy was 1582 days, while it was 315 days for those who did not receive therapy.<br /><br />The study concluded that, apart from activating EGFR mutations, early-stage lung carcinoma patients are usually treated irrespective of the specific driver mutation. However, there is a rapidly expanding landscape of targetable alterations, including rarer mutations, which may soon be considered for targeted therapy. The study also highlighted the potential benefit of adjuvant therapy in patients with KRASG12C mutated early-stage lung carcinomas, suggesting the need for future patient stratification.<br /><br />Overall, this study emphasizes the importance of characterizing and understanding the various mutation groups in surgically resected lung carcinomas. By doing so, researchers and clinicians can better identify appropriate targeted therapy options for patients, potentially improving their outcomes and providing more personalized treatment approaches.

Asset Subtitle

Luka Brcic

Meta Tag

Speaker Luka Brcic

Topic Early Stage Non-small Cell Lung Cancer - Biomarkers

Keywords

clinicopathological features

disease-free survival

surgically resected lung carcinomas

rare mutations

KRASG12C

BRAF

ALK fusion

METex14 skipping alterations

adjuvant therapy

targeted therapy